|
 |
Dynamis Skin Science is a division of Dynamis Therapeutics, Inc., an early stage pharmaceutical company. Dynamis Therapeutics was founded in 1997 by a team of scientists as a joint venture between Fox Chase Cancer Center (FCCC) in Philadelphia and a group of investors. It was originally funded by the Ben Franklin Technology Center, the National Institutes of Health as well as venture capital. The company scientists originally focused on the discovery and development of therapeutic pharmaceuticals to treat and prevent diabetic complications resulting from glucose induced glycation and oxidative stress. |
While testing compounds that might reduce these complications in diabetes, scientists from Philadelphia's Fox Chase Cancer Center unexpectedly noticed that a test compound had favorable effects on the texture and elasticity of skin. Further research and development resulted in Supplamine®, which address the effects on skin resulting from glycation and oxidative stress. As a result, Dynamis Skin Science division was established in 2006 to develop and market topical products containing Supplamine® to doctors and skin care professionals. The company has received significant additional funding from various investors including Rohto Pharmaceutical Co, Ltd., the Japanese licensee. Rohto is represented in the United States by its subsidiary, the Mentholatum Co, Inc., which manufactures various personal care products including those for lip care, pain relief, acne and eye care.
Dynamis Skin Science has its offices in Jenkintown, Pennsylvania (just north of Philadelphia), and its research laboratories nearby in Elkins Park, Pennsylvania and at the Fox Chase Cancer Center in Philadelphia, Pennsylvania. A percentage of the sale of the Dynamis Skin Science products is paid to Fox Chase Cancer Center to support continued basic cancer research.
|
|
